Células CAR-NK: Un modelo para la inmunoterapia tumoral. Revisión de la literatura
Palabras clave:
Células asesinas naturales, Receptores quiméricos de antígenos, Inmunoterapia, Tumor, CáncerResumen
El objetivo de esta revisión es describir los principios biológicos, inmunológicos, y oncológicos que, están asociados, con la fundamentación teórica de la utilización de las células CAR-NK, para la inmunoterapia tumoral. Desde el descubrimiento de las células asesinas naturales (en inglés Natural Killer Cells o células NK), se han presentado grandes avances en la comprensión de los mecanismos acción, y sus funciones relacionadas con el sistema inmunológico. Este conocimiento ha dado paso al desarrollo de las tecnologías y terapias prometedoras, como las basadas en las células NK modificadas genéticamente con los receptores quiméricos de antígenos (en inglés Chimeric Antigen Receptors o CAR) denominadas, por sus siglas en inglés, células CAR-NK que originalmente fueron diseñadas, para el tratamiento de diferentes tipos de cáncer, mostrando resultados potenciales en modelos animales. Se espera que los ensayos clínicos que se están desarrollando arrojen resultados positivos de las células CAR-NK, permitiendo conocer las ventajas y desventajas de este tipo de inmunoterapia.
Descargas
Referencias
Dobosz P, Dzieciątkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019; 10(2965):1-10. DOI: 10.3389/fimmu.2019.02965
Ortiz-Lazo E, Arriagada-Egnen C, Poehls C, Concha-Rogazy M. An Update on the Treatment and Management of Cellulitis. Actas Dermosifiliogr. 2019; 110(2):124-130. DOI: 10.1016/j.adengl.2019.01.011
Decker W, da Silva R, Sanabria M, Angelo L, Guimarães F, Burt B, et al. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2017;8(829):1-13. DOI: 10.3389/fimmu.2017.00829
Tan S, Li D, Zhu X. Cancer Immunotherapy: Pros, cons and beyond. Biomedicine & Pharmacotherapy. 2020; 124(109821):1-11. DOI: 10.1016/j.biopha.2020.109821
Riley R, June C, Langer R, Mitchell M. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18:175-196. DOI: 10.1038/s41573-018-0006-z
Hegde P, Chen D. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020; 52(1):17-35. DOI: 10.1016/j.immuni.2019.12.011
Xie G, Dong H, Liang Y, Ham J, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020; 59(102975):1-10. DOI: 10.1016/j.ebiom.2020.102975
Abel A, Yang C, Thakar M, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018; 9(1869):1-23. DOI: 10.3389/fimmu.2018.01869
Bi J, Wang X. Molecular Regulation of Nk Cell Maturation. Front Immunol. 2020; 11(1945):1-12. DOI: 10.3389/fimmu.2020.01945
Federici C, Shahaj E, Cecchetti S, Camerini S, Casella M, Lessi E, et al. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. Front Immunol. 2020; 11(262):1-24. DOI: 10.3389/fimmu.2020.00262
Xu Y, Zhou S, Lam Y, Pang S. Dynamics of Natural Killer Cells Cytotoxicity in Microwell Arrays with Connecting Channels. Front Immunol. 2017; 8(998):1-9. DOI: 10.3389/fimmu.2017.00998
Mantesso S, Geerts D, Spanholtz J, Kučerová. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Front Immunol. 2020; 11(607131):1-12. DOI: 10.3389/fimmu.2020.607131
Terrén I, Orrantia A, Vitallé J, Zenarruzabeitia O, Borrego F. NK Cell Metabolism and Tumor Microenvironment. Front Immunol. 2019; 10(2278):1-9. DOI: 10.3389/fimmu.2019.02278
Morrissey M, Williamson A, Steinbach A, Roberts E, Kern N, Headley M, et al. Chimeric antigen receptor that trigger phagocytosis. eLife. 2018; 7(e36688):1-21. DOI: 10.7554/eLife.36688
Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Letters. 2020; 472:175-180. DOI: 10.1016/j.canlet.2019.11.033
Esteso G, Aguiló N, Julián E, Ashiru O, Ho M, Martín C, et al. Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG. Front Immunol. 2021; 12(622995):1-11. DOI: 10.3389/fimmu.2021.622995
Feins S, Kong W, Williams E, Milone M, Fraietta J. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019; 94:S3-S9. DOI: 10.1002/ajh.25418
Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of Chimeric Receptor Composed Of Immunoglobulin-Derived V Regions And T-cell Receptor-Derived C Regions. Biochem Biophys Res Commun. 1987; 149(3):960-968. DOI: 0006-291X/87.
Irving BA, Weiss A. The Cytoplasmic Domain of the T cell Receptor ζ Chain is Sufficient to Couple to Receptor-Associated Signal Transduction Pathways. Cell. 1991; 64(5):891-901. DOI: 10.1016/0092-8674(91)90314-o
Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol Cancer Ther. 2018; 17(9):1795-1815. doi: 10.1158/1535-7163.MCT-17-1097
Liu E, Marin D, Banerjee P, Macapinlac H, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020; 382:545-53. DOI: 10.1056/NEJMoa1910607
Xia J, Minamino S, Kuwabara K. CAR-expressing NK cells for cancer therapy: a new hope. BioScience Trends. 2020; 14(5):354-359. DOI: 10.5582/bst.2020.03308
Bergman H, Sissala N, Hägerstrand H, Lindqvist C. Human NK-92 Cells Function as Target Cells for Human NK Cells – Implications for CAR NK-92 Therapies. Anticancer Research. 2020; 40:5355-5359. DOI: 10.21873/anticanres.14543
Zhao S, Han Z, Ji C, An G, Meng H, Yang L. The research significance of concomitant use of CAR-CD138-NK and CAR-CD19-NK to target multiple myelomas. European Journal of Inflammation. 2018; 16:1-9 DOI: 10.1177/2058739218788968
Zhao Z, Chen Y, Francisco N, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges. APSB 2018; 8(4):539–551.
Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021. DOI: 10.1038/s41434-021-00246-w
Jayaraman J, Mellody M, Hou A, Desai R, Fung A, Huynh A, et al. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020; 8(102931) DOI: 10.1016/j.ebiom.2020.102931
Pfefferle A, Huntington N. You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. Cancers. 2020; 12(706):1-23 DOI:10.3390/cancers12030706
Franks S, Wolfson B, Hodge J. Natural Born Killers: NK Cells in Cancer Therapy. Cancers. 2020; 12(2131):1-21. DOI: 10.3390/cancers12082131
Gang M, Marin N, Wong P, Neal C, Marsala L, Foster M, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020; 136(20): 2308-2318. DOI: 10.1182/blood.2020006619
Liu Q, Xu Y, Mou J, Tang K, Fu X, Li Y, et al. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model. Cytotherapy. 2020;22:552-562. DOI: 10.1016/j.jcyt.2020.06.003
Li Y, Hermanson D, Moriarity B, Kaufman D. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018; 23:181-192. DOI: 10.1016/j.stem.2018.06.002
Peng X, Chen L, Chen L, Wang B, Wang Y, Zhan X. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review). Experimental and Therapeutic Medicine. 2021; 21(340): 1-7. DOI: 10.3892/etm.2021.9771
United States National Library of Medicine. Clinical Trials [Internet]. Estados Unidos: NIH; [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/
Del Zotto G, Marcenaro E, Vacca P, Sivori S, Penade D, Della M, et al. Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B (Clinical Cytometry). 2017;92B:100-114 DOI: 10.1002/cyto.b.21508
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 8 Sep 2016 - Identifier NCT02892695, PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma; 8 Sep 2016 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02892695
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 25 Oct 2016 - Identifier NCT02944162, CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML; 25 Sep 2016 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02944162
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 17 Feb 2017 - Identifier NCT03056339, Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies; 17 Sep 2017 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03056339
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 9 Jul 2018 - Identifier NCT03579927, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma; 9 Jul 2017 [Consultado 7 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03579927
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 1 Oct 2018 - Identifier NCT03690310, Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma; 1 Oct 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03690310
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2 Oct 2018 - Identifier NCT03692767, Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma; 2 Oct 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03692767
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 31 Ene 2019 - Identifier NCT03824964, Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma; 31 May 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03824964
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 7 May 2019 - Identifier NCT03940833, Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM; 7 May 2017 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03940833
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 10 Nov 2020 - Identifier NCT04623944, Safety of Intravenous Allogeneic Engineered Natural Killer Cells in Adults With AML or MDS; 10 Nov 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04623944
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 20 Nov 2020 - Identifier NCT04639739, Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma; 20 Nov 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04639739
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 16 Mar 2021 - Identifier NCT04796675, Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies; 16 Mar 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04796675
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 16 Mar 2021 - Identifier NCT04796688, Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies; 16 Mar 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04796688
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 30 Ene 2020 - Identifier NCT03415100, Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours; 30 Ene 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03415100
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2 Oct 2018 - Identifier NCT03692663, Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer; 2 Oct 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03692663
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2 Oct 2018 - Identifier NCT03692637, Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer; 2 Oct 2020 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03692637
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 30 Abr 2019 - Identifier NCT03931720, Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor; 30 Abr 2019 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03931720
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 7 May 2019 - Identifier NCT03940820, Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors; 7 May 2019 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03940820
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 8 May 2019 - Identifier NCT03941457, Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer; 8 May 2019 [Consultado 9 Abr 2021]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03941457
Klingemann H, Boissel L, Toneguzzo F. Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells. Front. Immunol. 7:91. DOI: 10.3389/fimmu.2016.00091
Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology. 2020; 570-578. DOI: 10.1182/hematology.2020002547
Jamali A, Hadjati J, Madjd Z, Mirzaei H, Thalheimer F, Agarwal S, et al. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. Front. Immunol. 2020; 11(2028):1-13 DOI: 10.3389/fimmu.2020.02028
Ingegnere T, Mariotti F, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Front. Immunol. 2019; 10(957):1-10 DOI: 10.3389/fimmu.2019.00957
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Salutem Scientia Spiritus
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
